NPX-Healthcare-30.
Safety disclosure. Regulatory trust. GICS 35.
The Healthcare-30 adapts the NPX-100 eight-axis framework for GICS sector 35 companies. Error Culture (EC) is upweighted from 8% to 12% — the largest relative EC upweight in the NPX sub-index family — because healthcare companies face a fundamentally different EC obligation than other sectors: patient safety information that is withheld or minimized can cause deaths. The HC-30 EC sub-criteria explicitly score proactive adverse event disclosure, clinical trial transparency (ClinicalTrials.gov registration completeness), FDA warning letter acknowledgment quality, and device/drug recall communication timelines.
EC elevated to 12%. The highest Error Culture weight of any NPX sub-index.
EC rises from 8% → 12% because healthcare is the only GICS sector where operational errors have direct patient safety implications. DH rises from 5% → 8% because regulatory approval moats (FDA 510k clearance, PMA approval, orphan drug designation) create durable economic protection that is qualitatively different from the cost-advantage moats that Morningstar's standard framework captures. FC is reduced to 18% because clinical-stage revenue uncertainty makes precise EPS guidance difficult and less informative than pipeline milestone delivery.
Additional eligibility gates
- GATE-7 — Conviction or deferred-prosecution agreement involving patient safety data fraud or clinical trial data manipulation within the preceding 7 years (not just investigation — conviction required)
- GATE-8 — Active Class I FDA recall (most serious category, may cause serious adverse health consequences or death) involving a marketed device or drug, without evidence of remediation and honest public communication within 30 days of recall announcement
- GATE-9 — ClinicalTrials.gov registration rate below 90% for company-sponsored trials (retrospective audited against enrollment dates) — proxies for clinical trial transparency commitment
Sector-specific sub-criteria
- EC-H1 — Adverse event disclosure speed: calendar days from FDA reportable adverse event to public 8-K or press release communication, benchmarked against regulatory minimum (MEDWATCH timelines)
- EC-H2 — Clinical trial primary endpoint miss quality: depth of public explanation for missed endpoints — did the company explain the scientific hypothesis failure or only give forward-looking guidance?
- DH-H1 — Instrument/reagent lock-in: proportion of revenue from customers who standardized on an instrument platform requiring proprietary reagents (switching = repeating validation studies, typically 12–24 months)
DH = 88 from instrument/reagent lock-in: clinical labs that standardize on Danaher's diagnostic instruments (Beckman Coulter, SCIEX, Leica Biosystems) must use Danaher reagents and cannot switch mid-study protocol without re-running validation. The multi-year installed-base stickiness is among the strongest in life-science tools. GV 87, FC 88, EQ 87.
EC 84 — DBS quality system benchmark DH 88 — reagent lock-in GV 87
Where ICON excels: FC 85 from consistent revenue and operating margin guidance delivery, CD 83 from PRA Health Sciences integration discipline. ST 81 from published 3-year margin expansion targets. The GV constraint (dual-class structure, Waterford shareholder history) holds GV at 78. If governance structure normalizes, HC-30 composite would move to 84–86.
FC 85 — CRO guidance leader GV 78 — governance constraint
Healthcare companies that disclose failures earn higher scores. The EC upweight enforces this.
The HC-30 pool deliberately excludes high-growth pharmaceutical companies with limited error-culture records and clinical-stage biotechnology. The 10 candidates represent healthcare companies with multi-year public records on adverse event disclosure, regulatory communication quality, and instrument/diagnostic platform moats. NEW marks companies not in the NPX-100 founding pool.
| # | Company · sub-industry | Segment | HC-30 Score | Band | Category strength |
|---|---|---|---|---|---|
| 1 | Danaher CorporationDHR · NYSE · USLife Sciences Tools & Services | Life Science Tools | 88.6 |
Watch List | EC 84 — DBS quality system is the healthcare EC benchmark. DH 88 from instrument/reagent lock-in (Beckman Coulter, SCIEX, Leica). FC 88, EQ 87. GV 87. Post-Fortive separation, pure-play life science/diagnostics focus sharpens the HC-30 profile. |
| 2 | Novo Nordisk A/SNVO · NYSE ADR · DenmarkPharmaceuticals | GLP-1 / Diabetes | 88.1 |
Watch List | EC 86 — proactive cardiac safety disclosure on LEADER trial (liraglutide) set pharma EC benchmark in 2016. Published the trial before FDA requested, with full patient-level dataset. DH 87 from GLP-1 first-mover regulatory position. GV 88 from Novo Nordisk Foundation governance (prevents hostile acquisition). FC 87. |
| 3 | Thermo Fisher Scientific Inc NEWTMO · NYSE · USLife Sciences Tools & Services | Life Science Tools | 87.5 |
Watch List | ST 88 — Practical Impact Plan targets with segment-level disclosure updated annually. DH 87 from instrument/reagent lock-in across 95,000+ products, similar in structure to Danaher. FC 89, the highest in the HC-30 pool. CD 85. EC 78 (strong but below DHR/NVO benchmark). |
| 4 | IDEXX Laboratories Inc NEWIDXX · NASDAQ · USHealth Care Distributors | Vet Diagnostics | 86.6 |
Watch List | DH 92 — highest in HC-30 pool. Veterinary diagnostics platform lock-in is near-absolute. Veterinary practices that install IDEXX in-clinic analyzers use IDEXX reagent cartridges exclusively; switching requires re-equipping every analyzer across the practice. SK 88 from 90%+ vet practice retention. EQ 88. FC 85. |
| Engagement Pool · 75–84 · gate-clear, below watch-list threshold | |||||
| 5 | Chemed Corporation NEWCHE · NYSE · USHealth Care Facilities | Hospice / Plumbing | 84.5 |
Engagement Pool | VITAS Healthcare hospice EC record is the strongest patient-dignity disclosure in the sector. GV 86. EC 80 from proactive CMS audit response communications. The Roto-Rooter segment introduces conglomerate discount in HC-30 purity scoring (non-healthcare revenue = 40%). FC 84 from consistent multi-segment guidance delivery. |
| 6 | West Pharmaceutical Services IncWST · NYSE · USLife Sciences Tools & Services | Drug Containment | 84.2 |
Engagement Pool | DH 87 — drug container specification moat. Pharma manufacturers cannot switch container closure systems without FDA NDA/ANDA re-submission. EQ 86, CD 85, GV 85. EC 78 from quality-system transparency. Over 10,000 drug products manufactured in West Pharmaceutical components globally. FC constraint: no published EPS guidance. |
| 7 | Bio-Techne Corporation NEWTECH · NASDAQ · USLife Sciences Tools & Services | Research Reagents | 83.6 |
Engagement Pool | Research reagent specification moat — published methods cite Bio-Techne catalog numbers specifically. Researchers who replicate a prior study must use the same catalog numbers; switching breaks reproducibility. DH 86. EQ 87, CD 86, no long-term debt. FC 82 from limited formal guidance. EC 77 — stronger EC culture than typical specialty-reagent firms. |
| 8 | Medpace Holdings Inc NEWMEDP · NASDAQ · USLife Sciences Tools & Services | CRO / Clinical | 83.6 |
Engagement Pool | FC 87 — best forecast calibration in the CRO cohort. Medpace delivers revenue guidance within stated range more consistently than any peer CRO. Specialization in emerging biotech clients (vs large pharma) creates higher-growth profile. EC 79 from proactive protocol-deviation disclosure. GV 85. CD 84 from debt-free balance sheet. |
| 9 | DexCom Inc NEWDXCM · NASDAQ · USHealth Care Equipment | CGM Devices | 82.7 |
Engagement Pool | EC 84 — proactive G7 accuracy issue disclosure in 2023 is the CGM segment EC benchmark. DexCom immediately published accuracy data and remediation timeline rather than waiting for FDA action. DH 85 from sensor subscription model (patients calibrate to a specific sensor profile over months). FC 80 from high revenue growth volatility. GV 83. |
| 10 | ICON PLC NEWICLR · NASDAQ · IrelandLife Sciences Tools & Services | CRO / Clinical | 82.3 |
Engagement Pool | FC 85 — consistent CRO revenue and margin guidance delivery. EC limited by CRO structural constraint (sponsor controls adverse event disclosure). GV 78 from dual-class history. CD 83 from PRA integration discipline. ST 81 from 3-year margin targets. If governance normalizes, composite reaches 84–86. |
These are founding estimates. The methodology is in development.
Methodology status
NPX-Healthcare-30 methodology v0.1 is in development and has not been hash-committed. All 10 candidates carry K-basis (steward estimate) scores pending primary-source verification. The methodology will be published with a SHA-256 hash when it reaches v1.0 stability. EC sub-criteria in particular require primary-source verification of adverse event disclosure timelines against FDA MAUDE database records.
What this is not
These scores are not a constituent list, watch list, or investment recommendation. NPX-Healthcare-30 is planned for launch alongside the NPX-100 first quarterly publication cycle in 2027-Q1. No score published here implies a company meets the NPX-Healthcare-30 constituent standard. Patient safety records change; all EC scores should be treated as point-in-time estimates.